Delivery of therapeutic proteins through lactococcus lactis

Biotechnology and Genetic Engineering Reviews

Volumn 22, Issue 1, 2006, Pages 253-266

  Neirynck, Sabine ^a   Steidler, Lothar ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

LACTOCOCCUS LACTIS; THERAPEUTIC PROTEIN;

PROTEINS;

NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY; RECOMBINANT INTERLEUKIN 10; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TETANUS ANTIBODY; TREFOIL PEPTIDE;

ALLERGY; BACTERIAL GENE; BACTERIUM ISOLATE; COLITIS; DNA MODIFICATION; DRUG DELIVERY SYSTEM; FERMENTATION; FOOD INDUSTRY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INTESTINE; LACTIC ACID BACTERIUM; LACTOCOCCUS LACTIS; MICROFLORA; NONHUMAN; REVIEW; VACCINATION;

BACTERIA (MICROORGANISMS); LACTOCOCCUS LACTIS; LOTUS;

EID: 33645961321     PISSN: 02648725     EISSN: 20465556     Source Type: Journal    
DOI: 10.1080/02648725.2006.10648073     Document Type: Article

References (70)

1. Ahmad, S.I., Kirk, S.H. and Eisenstark, A. (1998). Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annual Review of Microbiology52, 591–625
2. Alpert, C.-A., Mater, D.D.G., Muller, M.-C, Ouriet, M.-F., Duval-Iflah, Y. and Corthier, G. (2003). Worst-case scenarios for horizontal gene transfer from Lactococcus lactis carrying heterologous genes to Enterococcus faecalis in the digestive tract of gnotobiotic mice. Environmental Biosafety Research2, 173–180
3. Anderson, M.H. (1992). Changing paradigms in caries management. Current Opinion in Dentistry2, 157–162
4. Beninati, C., Oggioni, M.R., Boccanera, M. et al. (2000). Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nature Biotechnology18, 1060–1064
5. Bermudez-Humaran. L.G., Langella, P., Cortes-Perez. N.G. et al. (2003). Intranasal immunization with recombinant Lactococcus Iactis secreting murine interleukin-12 enhances antigen-specific Th 1 cytokine production. Infection and Immunity71, 1887–1896
6. Biancone, L., Monteleone, I., Del Vecchio, B.C. Vavassori, P. and Pallone, F. (2002). Resident bacterial flora and immune system. Digestive and Liver Disease34 Suppl. 2, S37–S43
7. Bron, P.A., Benchimol. M.G., Lambert, J. et al. (2002). Use of the alr gene as a food-grade selection marker in lactic acid bacteria Applied and Environmental Microbiology68,5663–5670.
8. Chang. T.L.Y., Chang. C.H., Simpson. D.A. et al. (2003). Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proceedings of the National Academy of Sciences of the United States of America100, 11672–11677.
9. Contreras, A., Molin. S. and Ramos. J.L. (1991). Conditional-suicide containment system for bacteria which mineralize aromatics. Applied and Eiivironnmental Microbiology57, 1504–1508.
10. Cummings, J.H., MacFarlane, G.T. and Macfarlane, S. (2003). Intestinal bacteria and ulcerative colitis. Current Issues in Intestinal Microbiology4, 9–20
11. Dl Fabio. S., Medaglini, D., Rush, C.M. et al. (1998). Vaginal immunization of Cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV-16 antigens. Vaccine16, 485–492
12. Drouault. S., Juste. C., Marteau. P., Renault. P. and Corthier. G. (2002). Oral treatment with Lactococcus Iactis expressing Staphylococcus hyicus lipase enhances lipid digestion in pigs with induced pancreatic insufficiency. Applied and Environmental Microbiology68, 3166–3168
13. Duchmann. R., Schmitt, E., Knolle. P., Meyer Zum Buschenfelde, K.H. and Neurath. M. (1996). Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. European Journal of Immunology26, 934–938
14. Ehrlich. K., Plate. S., Stroff, T., Gretzer, B., Respondek, M. and Peskar, B.M. (1998). Peptidergic and cholinergic neurons and mediators in peptone-induced gastroprotection:role of cyclooxygeniase-2. American Journal of Physiology:Gastrointestinal and Liver Physiology274, G955–G964.
15. Fedorak. R.N., Gangl, A., Elson, C.O. et al. (2000). Recombinant human interleukin-10 in the treatment of patients with mild to moderately active Crohn’s disease. The Interleukin-10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology119, 1473–1482.
16. Fidel, P.L., Jr. and Sobel, J.D. (1996). Immunopathogencsis of recurrent vulvovaginal candidiasis. Clinical Microbiology Reviews9, 335–348
17. Fuss, I.J., Neurath, M., Boirivant, M. et al. (1996). Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. Journal of Immunology157, 1261–5270
18. Guarner, F., Casellas. F., Borruel, N. et al,. (2002). Role of microecology in chronic inflammatory bowel diseases. European Journal of Clinical Nutrition56 Suppl. 4, S34–S38.
19. Hillman. J.D. (2002). Genetically modified Streptococcus mutans for the prevention of dental caries. Antonic van Leeuwenhoek82, 361–366
20. Hillman, J.D., Johnson, K.P. and Yaphe, B.I. (1984). Isolation of a Streptococcus mutans strain producing a novel bacteriocin. Infection and Immunity44, 141–144
21. Hillman. J.D., Dzuback. A.L. and Andrews, S.W. (1987). Colonization of the human oral cavity by a Streptococcus mutans mutant producing increased bacteriocin. Journal of Dental Research66, 1092–1094
22. Hillman, J.D., Novak. J., Sagura. E. et al. (1998). Genetic and biochemical analysis of mutacin 11 40. a lantibiotic from Streptococcus mutans. Infection and Immunity66, 2743–2749.
23. Hillman. J.D., Brooks. T.A., Michalek, S.M., Harmon, C.C., Snoep. J.L. and Van Der Weijden, C.C. (2000). Construction and characterization of an effector strain of Strepto-coccus mutans for replacement therapy of dental caries. Infection and Immunity68, 543–549
24. Hirsch, A. (1952). The evolution of the lactic streptococci. Journal of Dairy Research19,290–293.
25. Hugot, J.P., Chamaillard, M., Zouali H. et al.,. (2001). Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature411, 599–603
26. Jensen, L.B., Ramos. J.L., Kaneva, Z. and Molin, S. (1993). A substrate-dependent biological containment system for Pseudomonas putitda based on the Escherichia coli gef gene. Applied and Environmental Microbiology59, 3713–3717
27. Kakazu. T., Hara, J., Matsumoto, T. et al. (1999). Type 1 T-helper cell predominance in granulomas of Crohn’s disease. American Journal of Gastroenterology94, 2149–2155
28. Knudsen, S.M. and Karlstrom, O.H. (1991). Development of efficient suicide mechanisms for biological containment of bacteria. Applied and Environmental Microbiology57, 85–92
29. Knudsen. S., Saadbye, P., Hansen, L.H. et al. (1995). Development and testing of improved suicide functions for biological containment of bacteria. Applied and Environmental Micro-biology61, 985–991
30. Krüger. C. Hu. Y., Pan. Q. et al. (2002). In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nature Biotechnology20, 702–706
31. Leenhouts. K., Bolhuis. A., Venema. G. and Kok, J. (1998). Construction of a food-grade multiple-copy integration system for Lactococcus lactis. Applied Microbiology and Biotechnology49, 417–423
32. Lehner.T., Caldwell, J. and Smith, R. (1985). Local passive immunization by monoclonal antibodies against streptococcal antigen I/II in the prevention of dental caries. Infection and Immunity50, 796–799
33. Ling. P., Gately, M.K., Gubler. U.et al. (1995). Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. Journal of Immunology154, 116–127
34. Magliani, W., Conti. S., De Bernardis, F. et al. (1997). Therapeutic potential of anti-idiotypic single-chain antibodies with yeast killer toxin activity Nature Biotechnology15, 155–158
35. Medaglini D,. Rush. C.M., Sestini. P. and Pozzi, G. (1997). commensal bacteria as vectors for mucosal vaccines against sexually transmitted diseases:vaginal colonization with recombinant streptococci induces local and systemic antibodies in mice. Vaccine15, 1330–1337.
36. Medaglini D., Oggioni, M.R. and Pozzi, G. (1998). Vaginal immunization with recombinant gram-positive bacteria. American Journal of Reproductive Immunology39, 199–208
37. Michalek. S.M., Gregory. R.L., Harmon, C.C. et al. (1987). Protection of gnotobiotic rats against dental caries by passive immunization with bovine milk antibodies to Streptococcus mutans. Infection and Immunity55, 2341–2347.
38. Mizuno. H., Sakamoto. C. Matsuda. K, et al. (1997). Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology112, 387–397
39. Molin. S., Boe. L., Jensen. L.B. et al. (1993). Suicidal genetic elements and their use in biological containment of bacteria. Annual Review of Microbiology47, 139–166
40. Molina. L., Ramos, C. Ronchel. M.C. Molin, S. and Ramos. J.L. (1998). Construction of an efficient biologically contained Pseudomonas putida strain and its survival in outdoor assays. Applied and Environmental Microbiology64, 2072–2078
41. Niessner. M. and Volk, B. A. (1995). Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clinical and Experimental Immunology101, 428–435.
42. Norton. P.M., Wells. J.M., Brown. H.W., MacPherson. A.M. and le Page. R.W. (1997). Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C. Vaccine15, 616–619
43. Nouaille. S., Ribeiro, L.A., Miyoshi. A. et al, (2003). Heterologous protein production and delivery systems for Lactococcus lactis. Genetics and Molecular Research2, 102–111.
44. Ogura.Y., Bonen. D.K. Inohara.N. et al. (2001). A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature411, 603–606
45. Platteeuw, C. Van Alen-Boerrigter, I., Van Schalkwijk, S. and DE Vos, W.M. (1996). Food-grade cloning and expression system for Lactococcus lactis. Applied and Environmental Microbiology62, 1008–1013
46. Polonelli. L. and Morace. G. (1987). Production and characterization of yeast killer toxin monoclonal antibodies. Journal of Clinical Microbiology25, 460–462
47. Poulsen. S.S., Thulesen, L. Christensen. L., Nexo. E. and Thim. L. (1999). Metabolism of oral trefoil factor 2 (TFF2)and the effect of oral and parenteral TFF2 on gastric and duodenal ulcer healing in the rat. Gut45, 516–522
48. Recorbet, G., Robert. C. Givaudan. A., Kudla. B., Normand. P. and Faurie. G. (1993). Conditional suicide system of Escherichia coli released into soil that uses the Bacillus subtilis sacB gene. Applied and Environmental Microbiology 59, 1361–1366
49. Repa, A., Grangette. C. Daniel. C. et al. (2003). Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine22, 87–95
50. Robinson. K., Chamberlain. L.M., Schofield. K.M., Wells. J.M. and le Page. R.W. (1997). Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nature Biotechnology15, 653–657
51. Rodrigues. S., Van Aken, E., Van Bocxlaer. S. et al. (2003). Trefoil peptides as proangiogenic factors in vivo and in vitro:implication of cyclooxygenase-2and EGF receptor signalling. FASEB Journal17, 7–16
52. Ronchel. M.C. and Ramos. J.L. (2001). Dual system to reinforce biological containment of recombinant bacteria designed for rhizoremediation. Applied and Environmental Microbiology67, 2649–2656
53. Sartor. R.B. (1997). Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. American Journal of Gastroenterology92, 5S-11S
54. Sartor. R.B. (2004). Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases:antibiotics, probiotics. and prebiotics. Gastroenterology126, 1620–1633
55. Schotte, L., Steidler. L., Vandekerckhove. J. and Remaut. E. (2000). Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme and Microbial Technology27, 761–765.
56. Schreiber. S. (2000). Genetics of inflammatory bowel disease:a puzzle with contradictions? Gut47, 746–747
57. Seegers. J, F. (2002). lactobacilli as live vaccine delivery vectors:progress and prospects. Trends in Biotechnology20, 508–515
58. Sorensen, K.I., Larsen, R., Kibenich, A., Junge, M.P. and Johansen, E. (2000). A food-grade cloning system for industrial strains of Lactococcus lactis. Applied and Environmental Microbiology66, 1253–1258
59. Steidler. L., Wells. J.M., Raeymaekers, A., Vandekerckhove, J., Fiers, W. and Remaut. E. (1995). Secretion of biologically active murine interleukin-2 by Lactococcus lactis subsp. Lactis. Applied and Environmental Microbiology61, 1627–1629
60. Steidler. L., Robinson. K., Chamberlain. L. et al. (1998). Mucosal delivery of murine interleukin-2 (1L-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infection and Immunity66, 3183–3189
61. Steidler, L., Hans, W., Schotte, L. et al. (2000). Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science289, 1352–1355
62. Steidler, L., Neirynck. S., Huyghebaert, N. et al. (2003). Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin-10. Nature Biotechnology21, 785–789
63. Tan. X.D., Chen. Y.H., Liu, Q.P., Gonzalez-Crussi. F. and Liu, X.L. (2000). Prostanoids mediate the protective effect of trefoil factor 3 in oxidant-induced intestinal epithelial cell injury:role of cyclooxygcnase-2. Journal of Cell Science113, 2149–2155
64. Taupin, D. and Podolsky, D.K. (2003). Trefoil factors:initiators of mucosal healing. Nature Reviews Molecular Cell Biology4, 721–732
65. Thim. L. and Mortz, E. (2000). Isolation and characterization of putative trefoil peptide receptors. Regulator Peptides90, 61–68
66. Tilg, H., Ulmer, H., Kaser, A. and Weiss, G. (2002). Role of IL-10 for induction of anaemia during inflammation. Journal of Immunology169, 2204–2209
67. Van Deventer. S.J., Elson. CO. and Fedorak, R.N. (1997). Multiple doses of intravenous interleukin-10 in steroid-refractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology113, 383–389
68. Van Dillewijn. P., Vilchez, S., Paz, J.A. and Ramos, J.L. (2004). Plant-dependent active biological containment system for recombinant rhizobacteria. Environmental Microbiology6, 88–92
69. Vandenbroucke, K., Hans, W., van Huysse, J. et al. (2004). Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology127, 502–513
70. Wells. J.M., Wilson. P.W., Norton, P.M., Gasson, M.J. and le Page, R.W. (1993). Lactococcus lactis:high-level expression of tetanus toxin fragment C and protection against lethal challenge. Molecular Microbiology8, 155–1162